RxDoctor Payments DataLook up a doctor →

Dhaval Patel, MD

Cardiovascular Disease · Marietta, GANPI 1831151174

Payments from drug & device makers

$72,921in general payments, 2019–2025

Across 508 payments — averaging $143.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$52K
  • United Therapeutics Corporation$8K
  • Actelion Pharmaceuticals US, Inc.$4K
  • Novartis$1K
  • Merck$1K
  • Pfizer$992
  • plus $5K from 34 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$72,921 in reported general payments places this provider in the 90th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$197,082
Medicare patients
2,114
Services billed
3,685

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →